Logo do repositório
 
Publicação

Efficacy and durability of the association of botox and skinvive in the treatment of moderate/severe wrinkles in the periorbital region : a randomized, controlled, double-blind, split-face clinical study

datacite.subject.fosCiências Médicas::Ciências da Saúde
datacite.subject.sdg03:Saúde de Qualidade
dc.contributor.authorNeves, Maria Luiza Boechat Borges
dc.contributor.authorThome, Cecilia
dc.contributor.authorSilva Junior, Silvio Ventura da
dc.contributor.authorMachado, Thalita
dc.contributor.authorSánchez-Ayala, Alfonso
dc.contributor.authorCâmara-Souza, Mariana Barbosa
dc.contributor.authorCanales, Giancarlo De la Torre
dc.date.accessioned2026-05-07T09:51:09Z
dc.date.available2026-05-07T09:51:09Z
dc.date.issued2025-08
dc.description.abstractBackground: The combined efficacy and durability of botulinum toxin A (BTX) and hyaluronic acid fillers (HA) for canthal wrinkles have not been thoroughly evaluated in randomized clinical trials. Aims: This study evaluated the efficacy, safety, and durability of the combined treatment protocol of onabotulinumtoxinA and Juvederm Volite VYC-12 (Skinvive) for moderate and severe canthal lines. Methods: This randomized double-blinded split-face trial included 25 women with periorbital dynamic wrinkles at severity levels II–IV according to the Merz 5-point scale. After bilateral onabotulinummtoxinA injections, the sides of the participants' faces were randomized to receive HA injections or a simulated injection. Assessed variables included electromyography activity (EMG), Merz 5-point crow's feet scale, and FACE-Q appraisal on crow's feet lines. Assessments were performed at baseline, 1, 2, 3, and 6 months. For differences in EMG and satisfaction scores, the two-way repeated measures ANOVA and Bonferroni's post hoc analyses were conducted. Wrinkle severity scores were analyzed with the Mann–Whitney U test. Results: Inter-treatment comparisons revealed no significant differences between treatment protocols in all assessed periods for EMG (p = 0.86). For severity of canthal wrinkles, onabotulinumtoxinA + VYC-12 exhibited lower canthal wrinkle severity in rest and contracted positions after 3 (p = 0.04), and 3 (p = 0.007) and 6 (p = 0.001) months, respectively. Additionally, satisfaction with BTX-HA treatment was significantly higher after 3-month (p = 0.001) and 6-month (p = 0.001) follow-ups compared to BTX treatment. Conclusions: Higher improvements in canthal wrinkles could be enhanced by using onabotulinumtoxinA and VYC-12 in association as a treatment protocol.eng
dc.identifier.citationM. L. B. B. Neves, C.Thome, S. V. da Silva Junior, et al., “Efficacy and Durability of the Association of Botox and Skinvive in the Treatment of Moderate/Severe Wrinkles in the Periorbital Region: A Randomized, Controlled, Double-Blind, Split-Face Clinical Study,” Journal of Cosmetic Dermatology, 24, no. 8 (2025): e70403, https://doi.org/10.1111/jocd.70403
dc.identifier.doi10.1111/jocd.70403
dc.identifier.issn1473-2165
dc.identifier.urihttp://hdl.handle.net/10400.26/63016
dc.language.isoeng
dc.peerreviewedyes
dc.publisherWiley
dc.relation.hasversionhttps://doi.org/10.1111/jocd.70403
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectbotulinum toxin type a
dc.subjectCanthal wrinkles
dc.subjecthyaluronic acid filler
dc.subjectonabotulinumtoxinA
dc.subjectVYC-12
dc.titleEfficacy and durability of the association of botox and skinvive in the treatment of moderate/severe wrinkles in the periorbital region : a randomized, controlled, double-blind, split-face clinical studyeng
dc.typecontribution to journal
dspace.entity.typePublication
oaire.citation.issue8
oaire.citation.startPagee70403
oaire.citation.titleJournal of Cosmetic Dermatology
oaire.citation.volume24
oaire.versionhttp://purl.org/coar/version/c_970fb48d4fbd8a85

Ficheiros

Principais
A mostrar 1 - 1 de 1
A carregar...
Miniatura
Nome:
Artigo_GDeLaTorreCanales_2025_05.pdf
Tamanho:
626.36 KB
Formato:
Adobe Portable Document Format
Licença
A mostrar 1 - 1 de 1
Miniatura indisponível
Nome:
license.txt
Tamanho:
1.85 KB
Formato:
Item-specific license agreed upon to submission
Descrição: